News Medical on MSN5d
Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell lineAsimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a nex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback